PRELUDE THERAPEUTICS INC Restructuring Costs
PRELUDE THERAPEUTICS INC (PRLD) reported Restructuring Costs of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC restructuring costs for the quarter ending 2026-06-30 was $0.00.
- PRELUDE THERAPEUTICS INC restructuring costs for the quarter ending 2026-03-31 was $0.00.
- PRELUDE THERAPEUTICS INC restructuring costs for the quarter ending 2025-06-30 was $0.00.
- PRELUDE THERAPEUTICS INC restructuring costs for the quarter ending 2025-03-31 was $0.00.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |